55 results
Page 3 of 3
6-K
EX-99.1
3xcmpmlwdlzm22w
9 Sep 19
Current report (foreign)
6:05am
6-K
EX-99.1
2o2fd7 onl2y5iqr
3 Sep 19
Current report (foreign)
8:20am
6-K
EX-99.1
2vv w1og7a7
30 Jul 19
Current report (foreign)
9:48am
6-K
EX-99.1
1l3i876thbgzxgvsbooq
24 Jun 19
GENFIT and Terns Pharmaceuticals Announce $228MM Strategic Partnership to Develop and Commercialize Elafibranor in Greater China
5:20pm
6-K
EX-99.1
165893dn 303v97a8u
5 Jun 19
GENFIT Launches a Phase 2 Trial Evaluating Elafibranor on Hepatic Lipid Composition for NAFL
7:40am
6-K
EX-99.1
0ryyt0 ryihaaza55
23 May 19
GENFIT Launches a Combination Therapy Clinical Program in NASH
5:13pm
6-K
EX-99.3
q4wjbbr
14 May 19
Shareholders' and Unitholders' Meetings
9:29am
6-K
EX-99.1
smwqzejc e1m3febzfi
18 Apr 19
GENFIT Announces FDA Grant of Breakthrough Therapy Designation to Elafibranor for the Treatment of PBC
6:04am
6-K
EX-99.1
mq9 pxffzhgbwpowm
15 Apr 19
GENFIT to Present Additional Data from the Positive Phase 2
8:01am
424B4
cqw2bn
27 Mar 19
Prospectus supplement with pricing info
4:12pm
F-1/A
qcm y97qk7em457crut7
14 Mar 19
Registration statement (foreign) (amended)
12:54pm
F-1
os0o1b0
27 Feb 19
Registration statement (foreign)
2:11pm
DRS/A
giu4isgza21y45zc
15 Feb 19
Draft registration statement (amended)
12:00am
DRS/A
yhx t5cse
21 Dec 18
Draft registration statement (amended)
12:00am
DRS
8oe32uzpvfan7huu7qbe
16 Nov 18
Draft registration statement
12:00am